124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY. (April 2015)